158 related articles for article (PubMed ID: 38474177)
1. Folate-Targeted Nanocarriers Co-Deliver Ganciclovir and miR-34a-5p for Combined Anti-KSHV Therapy.
Li F; Cao D; Gu W; Li D; Liu Z; Cui L
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474177
[TBL] [Abstract][Full Text] [Related]
2. Targeted delivery of miR-34a-5p by phenylborate-coupled polyethylenimide nanocarriers for anti-KSHV treatment.
Li F; Cao D; Yao L; Gu W; Liu Z; Li D; Cui L
Front Bioeng Biotechnol; 2023; 11():1343956. PubMed ID: 38260739
[TBL] [Abstract][Full Text] [Related]
3. miR-34a-5p inhibits the malignant progression of KSHV-infected SH-SY5Y cells by targeting c-fos.
Wu S; Wu Z; Xu H; Zhang J; Gu W; Tan X; Pan Z; Cao D; Li D; Yang L; Li D; Pan Y
PeerJ; 2022; 10():e13233. PubMed ID: 35444864
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 Vpr Inhibits Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication by Inducing MicroRNA miR-942-5p and Activating NF-κB Signaling.
Yan Q; Shen C; Qin J; Li W; Hu M; Lu H; Qin D; Zhu J; Gao SJ; Lu C
J Virol; 2016 Oct; 90(19):8739-53. PubMed ID: 27440900
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic KSHV-encoded interferon regulatory factor upregulates HMGB2 and CMPK1 expression to promote cell invasion by disrupting a complex lncRNA-OIP5-AS1/miR-218-5p network.
Li W; Wang Q; Feng Q; Wang F; Yan Q; Gao SJ; Lu C
PLoS Pathog; 2019 Jan; 15(1):e1007578. PubMed ID: 30699189
[TBL] [Abstract][Full Text] [Related]
6. In vitro antiviral drug sensitivity of the Kaposi's sarcoma-associated herpesvirus.
Medveczky MM; Horvath E; Lund T; Medveczky PG
AIDS; 1997 Sep; 11(11):1327-32. PubMed ID: 9302441
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-34a promotes genomic instability by a broad suppression of genome maintenance mechanisms downstream of the oncogene KSHV-vGPCR.
Krause CJ; Popp O; Thirunarayanan N; Dittmar G; Lipp M; Müller G
Oncotarget; 2016 Mar; 7(9):10414-32. PubMed ID: 26871287
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of MicroRNA 711 Mediates HIV-1 Vpr Promotion of Kaposi's Sarcoma-Associated Herpesvirus Latency and Induction of Pro-proliferation and Pro-survival Cytokines by Targeting the Notch/NF-κB-Signaling Axis.
Yan Q; Zhao R; Shen C; Wang F; Li W; Gao SJ; Lu C
J Virol; 2018 Sep; 92(18):. PubMed ID: 29976660
[TBL] [Abstract][Full Text] [Related]
9. Kaposi's sarcoma-associated herpesvirus microRNAs repress breakpoint cluster region protein expression, enhance Rac1 activity, and increase in vitro angiogenesis.
Ramalingam D; Happel C; Ziegelbauer JM
J Virol; 2015 Apr; 89(8):4249-61. PubMed ID: 25631082
[TBL] [Abstract][Full Text] [Related]
10. A Kaposi's sarcoma-associated herpes virus-encoded microRNA contributes to dilated cardiomyopathy.
Zhao Y; Li H; Du H; Yin Z; He M; Fan J; Nie X; Sun Y; Hou H; Dai B; Zhang X; Cai Y; Jin K; Ding N; Wen Z; Chang J; Chen C; Wang DW
Signal Transduct Target Ther; 2023 Jun; 8(1):226. PubMed ID: 37291118
[TBL] [Abstract][Full Text] [Related]
11. The Oncogenic Kaposi's Sarcoma-Associated Herpesvirus Encodes a Mimic of the Tumor-Suppressive miR-15/16 miRNA Family.
Morrison K; Manzano M; Chung K; Schipma MJ; Bartom ET; Gottwein E
Cell Rep; 2019 Dec; 29(10):2961-2969.e6. PubMed ID: 31801064
[TBL] [Abstract][Full Text] [Related]
12. Activated Nrf2 Interacts with Kaposi's Sarcoma-Associated Herpesvirus Latency Protein LANA-1 and Host Protein KAP1 To Mediate Global Lytic Gene Repression.
Gjyshi O; Roy A; Dutta S; Veettil MV; Dutta D; Chandran B
J Virol; 2015 Aug; 89(15):7874-92. PubMed ID: 25995248
[TBL] [Abstract][Full Text] [Related]
13. Modified Cross-Linking, Ligation, and Sequencing of Hybrids (qCLASH) Identifies Kaposi's Sarcoma-Associated Herpesvirus MicroRNA Targets in Endothelial Cells.
Gay LA; Sethuraman S; Thomas M; Turner PC; Renne R
J Virol; 2018 Apr; 92(8):. PubMed ID: 29386283
[TBL] [Abstract][Full Text] [Related]
14. miRNA Sequence Analysis in Patients With Kaposi's Sarcoma-Associated Herpesvirus.
Tuncer SB; Celik B; Akdeniz Odemis D; Kılıc Erciyas S; Sukruoglu Erdogan O; Avsar M; Kuru Turkcan G; Yazici H
Pathol Oncol Res; 2022; 28():1610055. PubMed ID: 35140551
[TBL] [Abstract][Full Text] [Related]
15. The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor as a therapeutic target for the treatment of Kaposi's sarcoma.
Montaner S; Sodhi A; Ramsdell AK; Martin D; Hu J; Sawai ET; Gutkind JS
Cancer Res; 2006 Jan; 66(1):168-74. PubMed ID: 16397229
[TBL] [Abstract][Full Text] [Related]
16. Discovery of Kaposi's sarcoma herpesvirus-encoded circular RNAs and a human antiviral circular RNA.
Tagawa T; Gao S; Koparde VN; Gonzalez M; Spouge JL; Serquiña AP; Lurain K; Ramaswami R; Uldrick TS; Yarchoan R; Ziegelbauer JM
Proc Natl Acad Sci U S A; 2018 Dec; 115(50):12805-12810. PubMed ID: 30455306
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA expression profiles in Kaposi's sarcoma.
Catrina Ene AM; Borze I; Guled M; Costache M; Leen G; Sajin M; Ionica E; Chitu A; Knuutila S
Pathol Oncol Res; 2014 Jan; 20(1):153-9. PubMed ID: 24027049
[TBL] [Abstract][Full Text] [Related]
18. Next-Generation Sequencing Analysis Reveals Differential Expression Profiles of MiRNA-mRNA Target Pairs in KSHV-Infected Cells.
Viollet C; Davis DA; Reczko M; Ziegelbauer JM; Pezzella F; Ragoussis J; Yarchoan R
PLoS One; 2015; 10(5):e0126439. PubMed ID: 25942495
[TBL] [Abstract][Full Text] [Related]
19. Complex Interactions between Cohesin and CTCF in Regulation of Kaposi's Sarcoma-Associated Herpesvirus Lytic Transcription.
Li D; Mosbruger T; Verma D; Swaminathan S
J Virol; 2020 Jan; 94(2):. PubMed ID: 31666380
[TBL] [Abstract][Full Text] [Related]
20. vFLIP-regulated competing endogenous RNA (ceRNA) networks targeting lytic induction for KSHV-associated malignancies.
Sheng L; Chen C; Chen Y; He Y; Zhuang R; Gu Y; Yan Q; Li W; Lu C
J Med Virol; 2022 Jun; 94(6):2766-2775. PubMed ID: 35149992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
